New hope for kids with tough cancers: Re-Engineered immune cells target leukemia
NCT ID NCT04571138
Summary
This study is testing a new cell therapy for children and young adults (up to age 30) whose leukemia or lymphoma has returned or not responded to other treatments. Doctors take a patient's own immune cells (T-cells), modify them in a lab to recognize a protein called CD22 on cancer cells, and then infuse them back into the patient. The goal is to see if this treatment is safe, can be made reliably, and if it helps eliminate the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Riley Hospital for Children
Indianapolis, Indiana, 46202, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.